Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis

OBJECTIVES: I. Assess the biosynthesis of cholesterol and cholestanol, and measure the turnover of individual sterols and bile acids in patients with cerebrotendinous xanthomatosis before and after a cholesterol- and cholestanol-free diet. II. Assess the biosynthesis of cholesterol and cholestanol, and measure the turnover of individual sterols and bile acids in these patients before and after...

Date First Received: October 18, 1999

Last Updated: June 23, 2005

Verified by: National Center for Research Resources (NCRR), December 2003

Clinical Trial Phase: Phase 2 | Start Date: January 1996

Overall Status: Recruiting

Estimated Enrollment: 5

Brief Summary

Official Title: “Effects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX)”

Condition Keyword(s):

OBJECTIVES: I. Assess the biosynthesis of cholesterol and cholestanol, and measure the turnover of individual sterols and bile acids in patients with cerebrotendinous xanthomatosis before and after a cholesterol- and cholestanol-free diet.

II. Assess the biosynthesis of cholesterol and cholestanol, and measure the turnover of individual sterols and bile acids in these patients before and after lovastatin and chenodeoxycholic acid.

Study Type: Interventional

Study Design: Treatment

Detailed Clinical Trial Description

PROTOCOL OUTLINE: Following a 2-week baseline assessment, patients participate in a feeding study for up to 3 weeks. The diet is free of cholesterol and cholestanol.

For the next 4 weeks, patients return to their typical diet and are medicated with daily lovastatin and chenodeoxycholic acid.

The feeding study is repeated for an additional 3 weeks, with the patient taking either lovastatin or chenodeoxycholic acid.

Intervention(s) in this Clinical Trial

  • Drug: chenodeoxycholic acid
  • Drug: lovastatin

Criteria for Participation in this Clinical Trial

  • PROTOCOL ENTRY CRITERIA: Cerebrotendinous xanthomatosis

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: N/A

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: National Center for Research Resources (NCRR)

Overall Clinical Trial Officials and Contacts

William Connor Study Chair Oregon Health and Science University  

Additional Information

Information obtained from ClinicalTrials.gov on August 29, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00004346

Study ID Number: NCRR-M01RR00334-0067

ClinicalTrials.gov Identifier: NCT00004346

Health Authority: United States: Federal Government

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.